Evidence map›Paper›PMID 35891315›Full record

ArticleVaccines2022

Trends in Varicella Burden of Disease Following Introduction of Routine Childhood Varicella Vaccination in Argentina: A 12-Year Time Series Analysis.

Norberto Giglio, Pieralessandro Lasalvia, Manjiri Pawaskar, Cintia I Parellada, Yaneth Gil Rojas, Paula Micone, Virginia V Babic, Silvina E Neyro

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Norberto GiglioHospital de Niños Ricardo Gutiérrez, Buenos Aires C1425EFD, Argentina.
Pieralessandro LasalviaNeuroEconomix, Bogotá D.C. 110831, Colombia.ORCID 0000-0002-8998-6608
Manjiri PawaskarMerck & Co., Inc., Vaccines, Rahway, NJ 19454, USA.
Cintia I ParelladaMSD Brazil, São Paulo 04583-110, Brazil.ORCID 0000-0002-8536-9274
Yaneth Gil RojasNeuroEconomix, Bogotá D.C. 110831, Colombia.
Paula MiconeHospital Carlos G Durand, Obstetrics, Buenos Aires C1405DCS, Argentina.
Virginia V BabicMSD Argentina, Buenos Aires B1605AZE, Argentina.
Silvina E NeyroMinisterio de Salud de la Nación, Dirección de Control de Enfermedades Inmunoprevenibles (DiCEI), Buenos Aires C1073ABA, Argentina.ORCID 0000-0001-8414-5589
El Hospital General de Agudos Carlos G. Durand · ARHospital General de Niños Ricardo Gutierrez · ARMerck & Co., Inc., Rahway, NJ, USA (United States) · USMicrosoft (Brazil) · BRMinisterio de Salud · AR

Funding

MSD (United States) N/A
6 · The paper itself

Abstract

One-dose universal varicella vaccination (UVV) was introduced in the Argentinian National Immunization Program in July 2015. This study examined the impact of one-dose UVV on varicella incidence and mortality in Argentina. Incidence and mortality data were obtained from official databases for pre-UVV (January 2008-June 2015) and post-UVV (July 2015-December 2019) periods. Time series analyses with autoregressive integrated moving average (ARIMA) modeling predicted varicella incidence and mortality in absence of UVV in the target (aged 1-4 years) and overall population. Predicted and observed values post-UVV were compared to estimate UVV impact. Mean annual incidence rates per 100,000 reduced from 1999 (pre-UVV) to 1122 (post-UVV) in the target population and from 178 to 154 in the overall population. Significant declines in incidence were observed, reaching reductions of 83.9% (95% prediction interval [PI]: 58.9, 90.0) and 69.1% (95% PI: 23.6, 80.7) in the target and overall populations, respectively, during peak months (September-November) post-UVV. Decreasing trends in mortality rate from 0.4 to 0.2 per 1,000,000 population were observed. Over the last four years, one-dose UVV has significantly reduced varicella burden of disease in Argentina. Continuous efforts to improve vaccination coverage rates and long-term follow-up are needed to better understand the benefits of the UVV program.

Indexed as

ARIMAinfectious disease burdensurveillancetime seriesvaricella vaccination

Identifiers

PMID35891315
PMCPMC9317722
OpenAlexW4286434259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.